Dr Reddy’s announces the Launch of Eszopiclone tablets C-IV
16 Apr 2014
Hyderabad-based Dr. Reddy's Laboratories today said that it has launched Eszopiclone Tablets (C-IV) in dosages of 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of 's insomnia drug Lunesta, following US FDA approval on Tuesday.
Lunesta is a prescription treatment approved by the FDA and marketed by Sunovion Pharmaceuticals (earlier Sepracor Inc till its acquisition by Dainippon Sumitomo Pharma of Japan in 2010).
Lunesta (eszopiclone) tablets C-IV brand and generic had combined US sales of approximately $887 Million MAT for the most recent 12 months ending in January 2014 according to IMS Health.
Dr. Reddy's Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100.
Eszopiclone (Lunesta) along with other "Z-drugs" including zolpidem (Ambien), zaleplon (Sonata) are the most commonly prescribed sedative hypnotics in the US.
Eszopiclone is not marketed in the European Union following a 2009 decision by the European Medicines Agency (EMA) denying it new active substance status, in which it ruled that eszopiclone was too similar to zopiclone to be considered a new patentable product.
